#United States #New York #Levi & Korsinsky #class action lawsuit #INOVIO Pharmaceuticals

Levi & Korsinsky Brings Class Action Against Inovio Pharmaceuticals

Levi & Korsinsky, LLP, a prominent law firm known for its focus on shareholder rights, has recently announced that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (NASDAQ: INO). This lawsuit raises allegations of securities violations, which could have significant implications for shareholders who invested in Inovio during the specified class period.

Overview of the Class Action

This legal action affects shareholders who purchased Inovio stock between October 10, 2023, and December 26, 2025, and subsequently suffered financial losses. If you fall within this category, it is crucial to explore your legal options. Joseph E. Levi, an attorney at Levi & Korsinsky, encourages affected shareholders to reach out for more information.

Allegations in the Lawsuit

The core of the lawsuit is built around claims that Inovio Pharmaceuticals made materially misleading statements regarding its business operations, particularly concerning its CELLECTRA device and its regulatory submissions. According to the complaint filed in the United States District Court for the Eastern District of Pennsylvania, the Plaintiff claims that:
1. The manufacturing processes for the CELLECTRA device were inadequate, which was not disclosed to shareholders.
2. Inovio was unlikely to meet its projected timeline for filing its Biologics License Application (BLA).
3. The company lacked sufficient data to support claims for accelerated approval by regulatory bodies.
4. Additionally, the prospects and potential market performance of the product were overstated, leading to inflated stock prices.

These allegations highlight significant failures to meet disclosure obligations which could affect investor decisions.

Legal Framework Protecting Investors

The class action lawsuit is rooted in violations of Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. These regulations are designed to protect investors from fraudulent practices by prohibiting false statements and misleading omissions in securities transactions.

Joseph E. Levi noted, “The PSLRA provides essential protections for investors harmed by alleged securities violations.” The detailed nature of the complaint points to a clear responsibility on the part of Inovio’s executives to provide accurate information to the market.

Claim Against Individual Defendants

The action also identifies individual defendants, alleging that they acted as controlling individuals under Section 20(a) of the Exchange Act. This section allows for additional claims against those in positions of power within the company who may have influenced misleading public disclosures, despite being aware of the underlying issues.

Impact on Stock Prices

The lawsuit brings forth concerns regarding how corrective disclosures made over this period led to sharp declines in Inovio’s stock price. Investors often react negatively to news that contradicts prior statements about a company's performance, which can lead to significant financial repercussions for shareholders.

Conclusion

For those impacted by Inovio Pharmaceuticals’ alleged misstatements, this lawsuit presents an opportunity to seek redress. Investors are encouraged to review the details, consider their eligibility to join the class action, and consult with legal professionals. Levi & Korsinsky, LLP's recognition in handling securities cases positions it as a leading firm for affected shareholders seeking justice. Motions for lead plaintiff are due by April 7, 2026.

For further information on this lawsuit, you can contact Joseph E. Levi, Esq., at [email protected] or call (212) 363-7500.